MX2019006725A - Polinucleotidos y polipeptidos de adenovirus. - Google Patents
Polinucleotidos y polipeptidos de adenovirus.Info
- Publication number
- MX2019006725A MX2019006725A MX2019006725A MX2019006725A MX2019006725A MX 2019006725 A MX2019006725 A MX 2019006725A MX 2019006725 A MX2019006725 A MX 2019006725A MX 2019006725 A MX2019006725 A MX 2019006725A MX 2019006725 A MX2019006725 A MX 2019006725A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- polypeptide sequences
- polynucleotides
- adenovirus
- adenovirus polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a secuencias de polinucleótido y de polipéptido aisladas derivadas del nuevo adenovirus ChAd157 de chimpancé, así como a polinucleótidos recombinantes, vectores, adenovirus, células y composiciones que comprenden dichas secuencias de polinucleótido y de polipéptido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1620968.6A GB201620968D0 (en) | 2016-12-09 | 2016-12-09 | Adenovirus polynucleotides and polypeptides |
PCT/IB2017/057738 WO2018104911A1 (en) | 2016-12-09 | 2017-12-07 | Adenovirus polynucleotides and polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006725A true MX2019006725A (es) | 2019-08-22 |
Family
ID=58222021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006725A MX2019006725A (es) | 2016-12-09 | 2017-12-07 | Polinucleotidos y polipeptidos de adenovirus. |
Country Status (15)
Country | Link |
---|---|
US (2) | US11414679B2 (es) |
EP (1) | EP3551224A1 (es) |
JP (1) | JP2020511114A (es) |
KR (1) | KR20190092471A (es) |
CN (1) | CN110300597A (es) |
AR (1) | AR110502A1 (es) |
AU (1) | AU2017371944B2 (es) |
BE (1) | BE1025029B1 (es) |
BR (1) | BR112019010906A2 (es) |
CA (1) | CA3045973A1 (es) |
EA (1) | EA201991116A1 (es) |
GB (1) | GB201620968D0 (es) |
IL (1) | IL266942A (es) |
MX (1) | MX2019006725A (es) |
WO (1) | WO2018104911A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
KR102471633B1 (ko) | 2016-02-23 | 2022-11-25 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
AU2018266705B2 (en) | 2017-05-08 | 2023-05-04 | Gritstone Bio, Inc. | Alphavirus neoantigen vectors |
CN111108203A (zh) * | 2017-07-17 | 2020-05-05 | 葛兰素史密丝克莱恩生物有限公司 | 狂犬病病毒抗原构建体 |
BR112020024285A2 (pt) * | 2018-06-12 | 2021-03-02 | Glaxosmithkline Biologicals S.A. | polinucleotídeos e polipeptídeos de adenovírus |
CN112601545A (zh) | 2018-08-07 | 2021-04-02 | 葛兰素史密丝克莱恩生物有限公司 | 工艺和疫苗 |
WO2020128012A1 (en) | 2018-12-21 | 2020-06-25 | Glaxosmithkline Biologicals Sa | Methods of inducing an immune response |
CA3140019A1 (en) * | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
WO2023250416A2 (en) * | 2022-06-22 | 2023-12-28 | Asklepios Biopharmaceutical, Inc. | Adenovirus-based nucleic acids and methods thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
WO1995014026A1 (en) | 1993-11-17 | 1995-05-26 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
ES2500490T3 (es) | 1997-08-29 | 2014-09-30 | Antigenics Inc. | Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente |
JP4426091B2 (ja) | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
AU5677399A (en) | 1998-08-20 | 2000-03-14 | Wistar Institute Of Anatomy And Biology, The | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
AU750587B2 (en) | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
ATE449105T1 (de) * | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
EP2570423B1 (en) | 2005-06-17 | 2023-05-03 | MSD Italia S.r.l. | Hepatitis C virus nucleic acid vaccine |
PT1957528E (pt) | 2005-11-30 | 2013-01-09 | Univ Copenhagen | Uma vacina de nucleótido |
WO2008114149A2 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
MX2010005860A (es) * | 2007-11-28 | 2010-06-22 | Univ Pennsylvania | Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos. |
BRPI0921927B8 (pt) | 2008-11-21 | 2021-08-31 | Koebenhavns Univ University Of Copenhagen | Sensibilização de uma resposta imune |
ES2898235T3 (es) | 2009-02-02 | 2022-03-04 | Glaxosmithkline Biologicals Sa | Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos |
WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
EP2678433B1 (en) | 2011-02-22 | 2017-05-03 | California Institute of Technology | Delivery of proteins using adeno-associated virus (aav) vectors |
CN107921118B (zh) | 2015-06-12 | 2022-11-08 | 葛兰素史密丝克莱恩生物有限公司 | 腺病毒多核苷酸和多肽 |
GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
-
2016
- 2016-12-09 GB GBGB1620968.6A patent/GB201620968D0/en not_active Ceased
-
2017
- 2017-12-07 BR BR112019010906A patent/BR112019010906A2/pt unknown
- 2017-12-07 WO PCT/IB2017/057738 patent/WO2018104911A1/en unknown
- 2017-12-07 KR KR1020197018883A patent/KR20190092471A/ko not_active Application Discontinuation
- 2017-12-07 US US16/466,683 patent/US11414679B2/en active Active
- 2017-12-07 JP JP2019530815A patent/JP2020511114A/ja active Pending
- 2017-12-07 AU AU2017371944A patent/AU2017371944B2/en active Active
- 2017-12-07 BE BE2017/5910A patent/BE1025029B1/fr not_active IP Right Cessation
- 2017-12-07 AR ARP170103442A patent/AR110502A1/es unknown
- 2017-12-07 CN CN201780074539.3A patent/CN110300597A/zh active Pending
- 2017-12-07 MX MX2019006725A patent/MX2019006725A/es unknown
- 2017-12-07 EA EA201991116A patent/EA201991116A1/ru unknown
- 2017-12-07 EP EP17838152.1A patent/EP3551224A1/en active Pending
- 2017-12-07 CA CA3045973A patent/CA3045973A1/en active Pending
-
2019
- 2019-05-28 IL IL266942A patent/IL266942A/en unknown
-
2022
- 2022-05-11 US US17/742,221 patent/US11795478B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA201991116A1 (ru) | 2019-12-30 |
BE1025029B1 (fr) | 2018-10-10 |
US11795478B2 (en) | 2023-10-24 |
AU2017371944B2 (en) | 2020-07-02 |
AU2017371944A1 (en) | 2019-06-20 |
US20190300905A1 (en) | 2019-10-03 |
KR20190092471A (ko) | 2019-08-07 |
US20220275397A1 (en) | 2022-09-01 |
US11414679B2 (en) | 2022-08-16 |
BE1025029A1 (fr) | 2018-10-02 |
WO2018104911A1 (en) | 2018-06-14 |
CN110300597A (zh) | 2019-10-01 |
JP2020511114A (ja) | 2020-04-16 |
AR110502A1 (es) | 2019-04-03 |
BR112019010906A2 (pt) | 2019-10-01 |
GB201620968D0 (en) | 2017-01-25 |
IL266942A (en) | 2019-07-31 |
CA3045973A1 (en) | 2018-06-14 |
EP3551224A1 (en) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006725A (es) | Polinucleotidos y polipeptidos de adenovirus. | |
MX2017016105A (es) | Polinucleotidos y polipeptidos de adenovirus. | |
MX2020013553A (es) | Polinucleotidos y polipeptidos de adenovirus. | |
MX2018016074A (es) | Vector adenoviral. | |
EA201791426A1 (ru) | Полипептид и иммуномодуляция | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
EA202091004A1 (ru) | Аденовирус и пути его применения | |
MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
EA202091074A1 (ru) | Аденовирус и его применения | |
MX2017004559A (es) | Receptores de celulas t. | |
PH12017501863A1 (en) | Bioconjugates and uses thereof | |
EP4059961A3 (en) | Anti-tau constructs | |
MX2019007152A (es) | Peptido novedoso. | |
MX2022013454A (es) | Moduladores de la actividad del complemento. | |
MX2021001460A (es) | Metodos y composiciones para secrecion de polipeptidos heterologos. | |
MX2021014856A (es) | Vacuna de tgf-beta. | |
WO2015200897A3 (en) | Neural cells expressing adenovirus e4orf1, and methods of making and using the same | |
ZA201904705B (en) | Recombinant bcg overexpressing phop-phor | |
IL286579A (en) | Polynucleotides, compositions, and methods for polypeptide expression | |
EA201890351A1 (ru) | Рекомбинантный orf-вирусный вектор | |
MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
EA202091104A1 (ru) | Аденовирус и пути его применения | |
IL272655A (en) | Recombinant adeno-associated vectors | |
AR101146A1 (es) | Proteína con actividad xilanasa | |
WO2017089780A3 (en) | Peptides |